Multicenter Automatic Defibrillator Implantation Trial

Generally, arrhythmic complications increase both morbidity and mortality rates in patients after ACS.

Patients who present with EMI with reduced LVEF as in less than or equal to 40% have increased risk of new onset atrial fibrillation, radiarrhythmias, and ventricular arrhythmias.

Ventricular arrhythmias are common after ACS and more common in patients with reduced LVES.

The MANITOU trial as a multicenter automatic defibrillator implantation trial demonstrated a 31% reduction in all-cause mortality, hazard ratio of 0.69, 95% confidence interval, 0.51 to 0.93 for prophylactic implantation of a cardiac defibrillator in patients with an LVEF of less than or equal to 30% who were at least 30 days after MI or three months after revascularization for MI and had an anticipated life expectancy longer than one year.

Generally, arrhythmic complications increase both morbidity and mortality rates in patients after ACS.

Patients who present with EMI with reduced LVEF, as in less than or equal to forty percent, have increased risk of new-onset atrial fibrillation, bradyarrhythmias, and ventricular arrhythmias.

Ventricular arrhythmias are common after ACS and more common in patients with reduced LVEF.

The MANITOU Trial, as in Multicenter Automatic Defibrillator Implantation Trial, demonstrated a thirty-one percent reduction in all-cause mortality, hazard ratio of point six nine, ninety-five percent confidence interval, point five one to point nine three, for prophylactic implantation of a cardiac defibrillator in patients with an LVEF of less than or equal to thirty percent who were at least thirty days after MI or three months after revascularization for MI and had an anticipated life expectancy longer than one year.